Alaunos Therapeutics (TCRT) Competitors $1.94 +0.07 (+3.74%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. NEUP, ALLR, NXTC, TXMD, IMCC, CTXR, PRPH, MRKR, BFRG, and ALVRShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Neuphoria Therapeutics (NEUP), Allarity Therapeutics (ALLR), NextCure (NXTC), TherapeuticsMD (TXMD), IM Cannabis (IMCC), Citius Pharmaceuticals (CTXR), ProPhase Labs (PRPH), Marker Therapeutics (MRKR), Bullfrog AI (BFRG), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors Neuphoria Therapeutics Allarity Therapeutics NextCure TherapeuticsMD IM Cannabis Citius Pharmaceuticals ProPhase Labs Marker Therapeutics Bullfrog AI AlloVir Neuphoria Therapeutics (NASDAQ:NEUP) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Which has more risk and volatility, NEUP or TCRT? Neuphoria Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500. Does the media favor NEUP or TCRT? In the previous week, Alaunos Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Alaunos Therapeutics and 2 mentions for Neuphoria Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.02 beat Neuphoria Therapeutics' score of 0.93 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neuphoria Therapeutics Positive Alaunos Therapeutics Positive Which has stronger earnings and valuation, NEUP or TCRT? Alaunos Therapeutics has lower revenue, but higher earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics$10K1,761.56-$15.49MN/AN/AAlaunos Therapeutics$6K713.27-$4.68M-$2.46-0.79 Do analysts recommend NEUP or TCRT? Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 124.12%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NEUP or TCRT more profitable? Neuphoria Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria TherapeuticsN/A N/A N/A Alaunos Therapeutics N/A -168.02%-121.37% Do institutionals and insiders have more ownership in NEUP or TCRT? 15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 0.7% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryNeuphoria Therapeutics beats Alaunos Therapeutics on 8 of the 13 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.28M$2.48B$5.73B$9.77BDividend YieldN/A1.67%4.40%4.03%P/E Ratio-0.7922.5030.4926.30Price / Sales713.27505.34384.4287.08Price / CashN/A178.3537.7259.08Price / Book1.176.4110.176.66Net Income-$4.68M$32.94M$3.26B$265.34M7 Day Performance-6.28%2.94%3.58%3.49%1 Month Performance-30.96%1.69%3.74%0.47%1 Year Performance-30.71%6.36%38.48%19.59% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics1.141 of 5 stars$1.94+3.7%N/A-41.4%$4.28M$6K-0.7940Positive NewsGap UpNEUPNeuphoria Therapeutics1.6932 of 5 stars$7.64-1.9%$21.00+174.9%N/A$14.36M$10K0.00N/AAnalyst ForecastALLRAllarity Therapeutics2.982 of 5 stars$0.91-0.5%$9.00+894.4%-71.4%$13.65MN/A0.0010News CoverageGap DownNXTCNextCure4.4446 of 5 stars$5.09-3.2%$25.50+401.0%-73.0%$13.64MN/A-0.2090Positive NewsTXMDTherapeuticsMD0.664 of 5 stars$1.16+1.7%N/A-40.7%$13.43M$2.56M0.00420IMCCIM Cannabis1.2024 of 5 stars$2.53-1.9%N/A-23.5%$13.28M$39.44M-4.69340Positive NewsGap UpCTXRCitius Pharmaceuticals3.123 of 5 stars$1.23-10.9%$53.00+4,208.9%-92.2%$13.08MN/A0.0020PRPHProPhase Labs1.06 of 5 stars$0.31-6.4%N/A-86.0%$12.98M$6.77M-0.25130MRKRMarker Therapeutics3.4735 of 5 stars$1.13-6.6%$13.17+1,065.2%-72.8%$12.79M$6.59M-0.8260News CoverageBFRGBullfrog AI0.8529 of 5 stars$1.26-4.5%N/A-51.0%$12.70MN/A-1.664Positive NewsALVRAlloVirN/A$2.50+1.6%N/A-86.0%$12.61MN/A-0.12110High Trading Volume Related Companies and Tools Related Companies Neuphoria Therapeutics Alternatives Allarity Therapeutics Alternatives NextCure Alternatives TherapeuticsMD Alternatives IM Cannabis Alternatives Citius Pharmaceuticals Alternatives ProPhase Labs Alternatives Marker Therapeutics Alternatives Bullfrog AI Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access